Brad Bolzon

Brad Bolzon, Ph.D. is the leader of the firm, architect of its strategy, and oversees operations across North America and Europe. Brad combines 13 years of global pharmaceutical industry leadership experience and 18 years as a venture capitalist. His track record consists of a multitude of successful investments including Amira, Okairos, Speedel, Quanticel, Novira, Flexion, Crispr, BioTie, Jecure, BlueRock, Black Diamond, Northern Biologics, Monte Rosa and the firm’s Discovery Engines that have collectively generated close to $1.7 billion in returns for Versant stakeholders. Over his tenure, he has translated that experience into building and developing the current Versant investment team.